

Johns Hopkins Engineering

Immunoengineering

Immunoengineering—Allergy and Autoimmunity

Tolerance Through Particles




JOHNS HOPKINS
WHITING SCHOOL
of ENGINEERING

Case Studies to Illustrate Design Principles


- Replicating tolerance at the cellular level - particles
- Replicating tolerance at the organ level - scaffolds
- Delivery of allergen immunotherapy

Cytokine-particles induce Tregs for Allergies

- IL-2 and TGF- β 1 have short half-lives and off-target effects
- Microparticles allow for sustained release, local release, and dose sparing
- Soluble = Limit effector
- Particle = Induce Treg




Chemokine Particles to Recruit Tregs (Dry Eye Disease)



- Slow release to establish a long-term gradient


Nanoparticle Design for Treating Multiple Sclerosis

- Nanoparticle size can be used as carriers to target specific organs (lymph node targeting)
- 400 nm more effective than 80 nm
 - Want to facilitate uptake
- Directly conjugated antigen
 - Controlled antigen loading
 - Controlled size and zeta potential
 - Bind less IgG
- Control over properties, extended shelf-life, ease of manufacturing




Combining Antigen & Immunomodulation

- Combine antigen & rapamycin
 - Colocalization - Both need to be in same particle or immunogenic
- Take advantage that most particles end up in the spleen
- Control over multiple challenges with pro-inflammatory signals




Tolerogenic Microparticles Prevent Type 1 Diabetes

- 2 particle sizes to control uptake
 - Ins. & Vit D3 in small microparticle
 - TGF-b1 & GM-CSF in large microparticle
- Recruit, polarize, and tolerize for T1D prevention







Emulsion Based Injections

- Incomplete Freud's adjuvant form emulsion
 - paraffin oil and mannide monooleate
- Combination with Dexamethasone for sustained release of antigen




Particles Compared to Cell-based Therapies

- Conjugate to surface of degradable particle
- 500 nm to mimic apoptotic fragments and enhance uptake in spleen
- High level of peptide conjugation required for Treg induction




OVA₃₂₃₋₃₃₉-PLG



PLP₁₃₉₋₁₅₁-PLG


Can do with hydrogels as well

- Encapsulation in hydrogel
- Allows infiltration of cells to control regulatory environment





Bypassing APCs with artificial nanoparticle APCs

- Create aAPCs by attaching peptide-loaded MHC on the surface of Nanoparticles
- Without co-stimulatory signal this leads to tolerance
- High density of signal is needed to induce tolerogenic signals through TCR



Inducing Tolerance with Antigen-Presenting Cell Mimicking Particles

- Antigen-specific therapy
 - Requires knowledge of peptide
- Works in both mouse models of Diabetes and MS
- Induce regulatory-like antigen-specific CD8⁺ T cells



Summary

- Particles allow spatial and temporal control over release of autoantigen and immunomodulatory factors
 - This leads to local induction of tolerance instead of systemic effects
- Particles may provide more cost-effective therapies when compared to biologic and cellular therapies
 - Shelf-life, scalability, standardization, manufacturing, availability
- Important considerations for particle therapy design
 - Administration route
 - Size
 - Shape
 - Surface charge
 - Antigen/chemokine loading technique
 - Material



JOHNS HOPKINS

WHITING SCHOOL
of ENGINEERING